Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 27.24 |
| Open | 27.23 |
| Bid | 27.77 x 1000 |
| Ask | 27.98 x 1200 |
| Day's range | 26.97 - 29.00 |
| 52-week range | 13.84 - 62.49 |
| Volume | |
| Avg. volume | 1,581,110 |
| Market cap | 1.169B |
| Beta (5Y monthly) | -0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | 84.00 |
- GlobeNewswire
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease.¹ Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease.² ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 point
- Zacks
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
- Simply Wall St.
Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst individual investors who own 69% of the shares, institutions hold 25%
If you want to know who really controls Cassava Sciences, Inc. (NASDAQ:SAVA), then you'll have to look at the makeup of its share registry...
